What is already known about this subject
- Lopinavir (LPV)/Ritonavir (RTV) may potentially interact with
contraindicated medications affecting its metabolism and may produce
life-threatening adverse drug reactions (ADRs) due to drug-drug
interactions (DDIs).
- Potential clinically significant life-threatening
DDIs of this combination
antiviral therapy used in the treatment of COVID-19 patients has not
systematically reviewed yet.